The Impact of the Entry of Biosimilars: Evidence from Europe

Overview of attention for article published in Review of Industrial Organization, April 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#23 of 312)
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

So far, Altmetric has seen 8 X posts from 6 X users, with an upper bound of 14,602 followers.

In 2018, @ProfFionasm, @sstern_mit and I wrote about the early years of the European experience with biosimilars 👩‍🔬🇪🇺👩‍⚕️ https://t.co/BkV9KNkUdM

RT @WNicholsonPrice: At #BiosimilarInnovation @UCILaw, @arieldora sharing what's up with biosimilars in Europe (presenting work w/ @ProfFio…

RT @WNicholsonPrice: At #BiosimilarInnovation @UCILaw, @arieldora sharing what's up with biosimilars in Europe (presenting work w/ @ProfFio…

At #BiosimilarInnovation @UCILaw, @arieldora sharing what's up with biosimilars in Europe (presenting work w/ @ProfFionasm & @sstern_mit). Paper published here: https://t.co/Bv0wqzHLY8 (Nice caveat: 'Feedback welcome, but the paper's not changing').

RT @arieldora: + our paper on the first several years of the European experience: https://t.co/BkV9KNkUdM

+ our paper on the first several years of the European experience: https://t.co/BkV9KNkUdM